之前在关注名单里排第二 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholan…
Phase 2 drug target engagement study of PLN-74809 in patients with idiopathic pulmonary fibrosis using a novel αvβ6 cystine knot PET imaging tracer2236 Introduction: Molecular imaging holds great potential to advance our understanding of pulmonary fibrosis and accelerate the development of novel ...
INTEGRIS-PSC phase 2a study: evaluating the safety, tolerability, and pharmacokinetics of bexotegrast (PLN-74809) in participants with primary sclerosing cholangitisdoi:10.1016/S0168-8278(23)01037-1Gideon HirschfieldPalak TrivediCynthia LevyChristoph Schramm...